WO2005054486A1 - 遺伝子導入試薬調製法 - Google Patents
遺伝子導入試薬調製法 Download PDFInfo
- Publication number
- WO2005054486A1 WO2005054486A1 PCT/JP2004/018426 JP2004018426W WO2005054486A1 WO 2005054486 A1 WO2005054486 A1 WO 2005054486A1 JP 2004018426 W JP2004018426 W JP 2004018426W WO 2005054486 A1 WO2005054486 A1 WO 2005054486A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- cationic
- cells
- cell
- introducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to the use of a cationic amphipathic molecular assembly that has been self-threaded, a method for preparing the same, and the like.
- Methods for introducing genes into cells without using viruses include the calcium phosphate method, a method using DEAE-dextran reagent, and the like, lipofectin (trade name) ⁇ lipofectamine (trade name), and lipofectamine.
- lipofectin trade name
- lipofectamine trade name
- lipofectamine cationic ribosomes
- methods using microinjection or electoral poration methods are not suitable for processing large numbers of cells due to the fact that expensive »must be purchased and the operation requires skill. Absent.
- the present inventors have proposed a method for efficiently introducing a gene into cells instead of a conventional method for introducing a gene into a cell, which is simple in operation, has no cytotoxicity, and a ribosome composed of an amphipathic molecule.
- a method for efficiently introducing a gene into cells instead of a conventional method for introducing a gene into a cell, which is simple in operation, has no cytotoxicity, and a ribosome composed of an amphipathic molecule.
- the introduction efficiency into part of cells of the nervous cells and the like is not still sufficient, and further improvement of the efficiency of introducing s i RNA has been demanded.
- a method for introducing a peptide or protein into a cell for example, a method is known in which a peptide called a protein transduction domain (PTD) is bound to a protein or the like to introduce a target protein or the like into a cell.
- PTD protein transduction domain
- an object of the present invention is to provide a cationic and amphiphilic molecular assembly capable of introducing a compound such as a nucleic acid or a peptide into a cell with high efficiency, and a method for preparing the same.
- the present inventors have conducted intensive studies to achieve the above object, and for example, mixed an aqueous solvent and a cationic amphipathic molecule at a temperature of 40 ° C. or less, and prepared the cationic amphiphilic molecule.
- a cationic cationic amphiphilic aggregate obtained by self-fibrilation of nucleic acids, it is possible to produce desired compounds such as nucleic acids and peptides with extremely high efficiency compared to conventional methods using ribosomes and the like. They have found that they can be introduced into cells, and have completed the present invention.
- the present invention relates to the following.
- a method of preparing a cationic amphipathic molecule aggregate for use in introducing a conjugated compound into cells comprising converting a cationic amphiphilic molecule into a self-filament fiber.
- the cationic amphiphilic molecule has the formula (I)
- n represents an integer of 2 to 11
- X represents Br or C1.
- r is an integer of 12 to 16, s is 2 to: an integer of L1, and X is Br or C1
- t represents an integer of 12 to 16
- u represents 2 to: an integer of L1
- X represents Br or C
- a compound according to the above (6) which is a compound selected from the group consisting of a compound represented by X- (wherein, V represents an integer of 12 to 16, and X represents Br or C1).
- a method for introducing a conjugate into a cell comprising removing the complex of the cationic amphiphilic aggregate and the compound according to (11) and the cell.
- a method for introducing a compound into a cell in a living body which comprises administering to the subject a complex of the cationic amphipathic molecule aggregate according to (11) and a compound.
- (22) Use of the cationic amphiphilic molecular assembly according to (11) for producing an agent for introducing a compound into a cell.
- a method for introducing a compound into a cell comprising contacting a cell with a complex of a self-fused anionic amphiphilic molecular assembly and a conjugate.
- a method of introducing a compound into cells in a living body which comprises administering to the target a complex of a self-amplified cationic amphiphilic molecular assembly and a compound.
- nucleic acids can be introduced into nerve cells and the like with low efficiency with high efficiency, and siRNA can be introduced into cells with high efficiency.
- Figure 1 shows the difference in gene (plasmid DNA) transfer efficiency due to the difference in the preparation method.
- the white column shows the ratio of gene-generated cells when the aggregate prepared at 25 ° C was used.
- the black column shows the ratio of gene-generated cells when the ribosome prepared at 50 ° C was used.
- FIG. 2 shows the difference in siRNA introduction efficiency due to the difference in the preparation method.
- the open circles indicate the aggregates prepared at 25 ° C: ⁇ , and the closed circles indicate the expression levels of the ⁇ target genes using ribosomes prepared at 50 ° C.
- FIG. 3 is a graph showing the results of transfection of siRNA into each mouse ⁇ . a indicates lung, b indicates liver, and cd indicates kidney. Detailed description of the invention
- the present invention relates to the use of a self-fiberized cationic amphiphilic molecular assembly and a method for preparing the same.
- the cationic amphipathic molecular aggregate can be prepared by any method as long as the aggregate is applicable to the following uses (for example, introduction of a compound into cells). As a preferred method, for example, the following method can be mentioned.
- the cationic cationic amphipathic molecule is self-induced.
- the method requires the use of "cationic amphiphilic molecules”.
- Amphiphilic molecule refers to a synthetic molecule having a hydrophilic part and a hydrophobic part in the same molecule.
- amphiphilic molecules used in the present invention need to be cationic. This is because a compound such as an anionic nucleic acid and a cationic amphipathic molecule can form a stable complex by non-co-mingling with each other.
- the anionic amphiphilic molecule is a synthetic molecule.
- the “cationic amphipathic molecule” used in the present invention is applied to the introduction of a compound (nucleic acid, etc.) into a cell by the aggregation force of the cationic amphipathic molecule that has been converted into a self-filament II.
- the hydrophilic part preferably has a quaternary ammonium group.
- the “cationic amphiphilic molecule” used in the present invention has the formula (I) H 3 ) 3 (I)
- n represents an integer of 2 to 11
- X represents Br or C1.
- r represents an integer of 12 to 16
- s represents an integer of 2 to 11
- X represents Br or C'1.
- V represents an integer of 12 to 16, and X represents Br or C1
- m is preferably 12 to 14, more preferably 12 or 14.
- n is preferably from 2 to 8, and more preferably selected from the group consisting of 2, 4, 6 and 8.
- X is preferably Br.
- p is preferably 12 to 14, more preferably 12 or 14.
- q is preferably an integer selected from the group consisting of f and 2 to 6, more preferably 2, 4 and 6. More preferably, q is 2 or 4 when X is Br, and q is 6 when X is C 1.
- r is preferably 12 to: L4, more preferably 12 or 14.
- s is preferably an integer selected from the group consisting of 2 to 6, more preferably 2, 4 and 6, and even more preferably 2.
- t is preferably 12 to 14, more preferably 12 or 14, and even more preferably 14.
- u is preferably selected from the group consisting of 2 to 6, more preferably 2, 4 and 6, and still more preferably 2.
- X is preferably 1.
- V is preferably selected from the group consisting of 12, 14 and 16.
- X is preferably Br. From the viewpoints of the stability of the aggregate and the introduction efficiency of the conjugate (nucleic acid and the like), among the above compounds, the compound represented by the formula (IV) is more preferable.
- the most preferred cationic amphiphilic molecule used in the present invention is a compound represented by the formula (IV) in which t is 14, 2, and X is C1, that is, a compound represented by the formula (VI)
- the cationic amphiphilic molecule before preparation is not particularly limited, but is preferably a solid, and more preferably a powder.
- the cationic amphiphilic molecule before preparation is not particularly limited, and preferably does not form ribosome.
- cationic amphiphilic molecules are hydrophobically bound in a solvent such as 7 It means to form an aggregate by assembling through non-covalent bonds such as.
- “Side-side oxidation” means that molecules are aggregated to form an aggregate.
- the "operations to artificially induce aging” include sonication, ponoletex, ethanol / re injection method, French'press method, cholic acid method, Ca2 + fusion method, single melting angle method, calo This includes operations to apply physical stimuli such as heat.
- ribosomes are artificially formed by an ultrasonic generator or the like as in the conventional method, the introduction efficiency of compounds (nucleic acids and the like) is rather reduced.
- the “aggregate of amphipathic” refers to an aggregate formed by assembling of amphipathic molecules by self-filtration, which is difficult to identify as a single state.
- the body there are two ribosomes formed by hydrophobic bonding of the amphiphilic ⁇ hydrophobic parts, multiple vesicles, string-like aggregates, disk-like aggregates, lamellar-like aggregates, rod-like aggregates, etc. Mixture; ⁇ included.
- the “aggregate of ⁇ philicity ⁇ ” exists as a mixture of aggregates in the Sukhomi state.
- a water-soluble solvent is preferably mixed with the cationic amphiphilic molecule in order to convert the cationic amphiphilic molecule into a self-filament fiber.
- the “aqueous solvent” used in the preparation method of the present invention is not particularly limited as long as the aggregate obtained by the method is applicable to the introduction of a compound into cells.
- a compound e.g., physiological saline, phosphate-buffered saline (PBS), media used by those skilled in the art for normal cell culture (eg, RPMI 164, DMEM, HAM F-12, kt land).
- PBS phosphate-buffered saline
- media used by those skilled in the art for normal cell culture eg, RPMI 164, DMEM, HAM F-12, kt land.
- the aqueous solvent does not contain proteins such as serum. This is because proteins may inhibit the amphiphilic molecules from becoming self-reliant.
- the ⁇ ⁇ of the ionic solvent is not particularly limited, it is preferably in the range of ⁇ 4 to 10, more preferably in the range of ⁇ 7 to 8.
- a mixture of a 7_ solvent and anionic amphipathic molecule is prepared.
- the concentration is not particularly limited as long as it is applicable to the introduction of the aggregate conjugate obtained by the method into cells, but is preferably 40 ° C. or lower.
- the temperature is not particularly limited, but is preferably 40 ° C. or lower, more preferably 38 ° C. or lower, still more preferably 36 ° C. or lower, and most preferably 34 ° C. or lower.
- Preparing the cationic amphiphilic molecule aggregate at a temperature exceeding 40 ° C inhibits the self-fragmentation of the cationic amphipathic molecule, and inhibits the formed cationic amphiphilic molecule assembly. Coalescence becomes unstable, and the introduction efficiency of chemical (nucleic acid etc.) when using the aggregate decreases.
- the temperature of the liquid mixture is preferably higher than the freezing point of the liquid mixture for convenience in operation.
- the freezing point depends on the composition of the aqueous solvent, the type of the cationic amphipathic molecule, the concentration, etc., and is difficult to set uniformly, but it is difficult to uniformly set the solidification point. If it is more preferably 2 ° C or more, still more preferably 3 ° C or more, and most preferably 4 ° C or more, it does not cause many age problems.
- the liquid mixture freezes, making it difficult to continue the operation.
- the temperature of the mixed solution is preferably 1 ° C or more and 40 ° C or less, more preferably 2 ° C or more and 38 ° C or less, still more preferably 3 ° C or more and 36 ° C or less, most preferably. It is in the range of 4 to 34 ° C.
- a mixed solution is obtained by first mixing an aqueous solvent and a cationic amphiphilic molecule.
- the concentration of the cationic amphiphile in the liquid mixture can be appropriately set in consideration of the type of the cationic amphiphilic molecule used. 2200 mM, preferably 1-10 O mM, more preferably 1-5 O mM, more preferably 5-50 mM, most preferably 1 O-30 mM.
- concentration is too low, a sufficient amount of cationic amphiphilic molecular aggregates will not be formed, and if the concentration is too high, cationic amphiphilic molecules may precipitate.
- the cationic amphipathic molecule is self-threaded, and an aggregate is formed.
- the above-mentioned operation such as ultrasonic treatment for inducing the artificial yarn is not performed.
- the mixture is left standing or gently stirred (for example, by pipetting).
- the mixture is incubated in a thermostat to control the temperature.
- the incubation time can be appropriately set in consideration of conditions such as the type of the cationic ⁇ amphiphilic molecule used, but is usually 1 to 96 hours, preferably 1 to 72 hours, more preferably The range is 1 to 48 hours, more preferably 1 to 24 hours, and most preferably 2 to 24 hours.
- the desired compound By using a cationic amphipathic molecular aggregate (for example, the aggregate prepared by the method of the present invention) that has been converted into a self-threaded yarn, the desired compound can be introduced into cells with extremely high efficiency. It is possible to do.
- the compound that can be introduced into cells using the aggregate is not particularly limited as long as the compound can be introduced. Examples thereof include nucleic acids, peptides, proteins, lipids, sugars, and physiological activities.
- Substances and drugs Doxorubicin (antitumor key), Daunorubicin (antitumor drug), Vincristine (antitumor drug), Vinblastine (antitumor drug), Idarubicin (antitumor drug), Dibucaine (local anesthetic), Propranolol () 3 blockers), Quinidine (antiarrhythmic drug), Dopamine (intensity and vasopressor), Imipramine (antidepressant), Diphenhydramine (antihistamine), Quinine (antimalarial), Chloroquine 3 ⁇ 4 malaria, Diclofenac Inflammatory drugs) and the like, and moisturizing agents for cosmetics and the like (mannitol and the like).
- nucleic acid DNA or RNA can be used as the “nucleic acid”.
- the type of DNA can be appropriately selected according to the purpose of use, and is not particularly limited. Examples thereof include plasmid DNA, antisense DNA, chromosomal DNA, PAC, and BAC, and preferably plasmid DNA, Antisense DNA, and more preferably, plasmid DNA. Circular DNA such as plasmid DNA can be appropriately digested with a restriction enzyme or the like and used as linear DNA.
- RNA can be appropriately selected according to the purpose of use, and is not particularly limited. Examples thereof include si RNA, antisense RNA, messenger RNA, transfer RNA, and liposomal RNA. Is siRNA or antisense RNA, and more preferably siRNA.
- siRNA self-assembled cationic amphipathic molecular aggregates (for example, the aggregates prepared by the method of the present invention), compared with conventional methods using ribosomes, It is possible to introduce siRNA into cells with high efficiency.
- the nucleic acid is a single-stranded or double-stranded one, preferably a single- or double-stranded nucleic acid.
- the nucleic acid may be modified such as by phosphorothioation.
- the size of the nucleic acid is not particularly limited, and is a large nucleic acid molecule such as a chromosome (artificial chromosome).
- the size of a high nucleic acid such as plasmid DNA is 2 to 15 kbp, preferably 2 to 10 kbp.
- the size of a low-molecular-weight nucleic acid such as siRNA is 5 to 50 bp, preferably 10 to 30 bp.
- the nucleic acid may be either naturally occurring or synthesized, but if it has a size of about 100 bp or less, a commonly used automatic nucleic acid synthesizer can be used by the phosphotriethyl method, the phosphodiester method, or the like. It is possible to synthesize using.
- the nucleic acid used in the present invention is not particularly limited, but is preferably purified by a method usually used.
- Maako a compound that can be introduced into cells using the cationic cationic amphipathic molecular assembly that has been made into a self-filament fiber, is required from the viewpoint of the stability of the complex with the cationic cationic amphipathic molecular assembly. From the viewpoint of being anionic, it is preferred that the compound be anionic, but in addition to a cationic or neutral water-soluble compound, a lipid-soluble compound may be used.
- the cationic amphipathic molecular aggregate In order to use the above cationic amphipathic molecular aggregate for introducing a compound (nucleic acid, etc.) into cells, the cationic amphiphilic molecular aggregate is brought into contact with a compound (nucleic acid, etc.). As a result, a complex (hereinafter sometimes simply referred to as “complex”) between the aggregate and a compound (nucleic acid or the like) is formed. Since the aggregate is cationic, it forms a non-covalent association with an anionic compound (nucleic acid or the like) to form a stable complex.
- a complex of a cationic amphipathic molecular aggregate and a compound (nucleic acid or the like) can be obtained by mixing an aqueous solvent containing the aggregate with a compound (nucleic acid or the like) and incubating the mixture.
- the type of the aqueous solvent is the same as described above.
- the time of the incubation is set in the same range as in the method for preparing the cationic amphipathic molecular assembly.
- the concentration of the cationic cationic amphipathic molecule aggregate in the mixed solution can be appropriately set in consideration of the type of cationic cationic amphipathic molecule used, etc., and is usually 0.05 to 500 mM, for example, 1 to 500 mM. 20 OmM, preferably :! 1010 OmM, more preferably 1-5 OmM, even more preferably 5-50 mM, most preferably 10-30 mM.
- concentration is too low, a sufficient amount of the complex will not be formed, and if the concentration is too high, a cationic amphiphilic molecular aggregate may be precipitated.
- the concentration of the compound (nucleic acid or the like) in the mixture can be appropriately set in consideration of the type and size (molecular weight) of the compound to be used, but when the compound is DNA, it is usually 3 to: L00 ng / nL. Range.
- the DNA concentration in the mixture is preferably 10 to 90 ng / ⁇ L, more preferably 20 to 80 ngZL, and still more preferably 30 to 80 ng / L. 7070 ng / ⁇ L, most preferably in the range of 40-60 ng ZL.
- the concentration is too low, the DNA introduced into the cells cannot exhibit the expected function, while if the concentration is too high, the nucleic acid introduction efficiency will decrease.
- the concentration of # ⁇ which is RNA as the compound, can be appropriately set in consideration of the size of RNA, etc., but if the size of RNA is about several kbp ⁇ , the RNA concentration in the above mixture is Usually between 3 and 100 ng L, preferably between 10 and 90 ng / L, more preferably between 20 and 80 ng ZL, more preferably between 30 and 70 ng / L, most preferably between 40 and 60 ng / ⁇ L. is there.
- the RNA concentration is usually 1-500 nM, preferably 20-400 nM, more preferably It is preferably in the range of 20 to 300 nM, more preferably 20 to 200 nM, most preferably 20 to: L000 nM.
- the concentration is too low, the RNA introduced into the cells will not be able to express the expected function, and if the concentration is too high, the nucleic acid introduction efficiency will decrease.
- the incubation time after mixing the aqueous solvent containing the aggregate with the compound (nucleic acid, etc.) can be determined in consideration of conditions such as the type of reagent used. ⁇ 100 minutes, preferably 0.5-30 minutes, more preferably 0.5-10 minutes, even more preferably 0.5-2 minutes, most preferably 0.5-1 minute. .
- the compound (such as nucleic acid) will have a single amphipathic molecular assembly
- a compound (nucleic acid or the like) contained in the complex can be introduced into the cell.
- the type of the “cell” is not particularly limited, and may be a prokaryote or a cell of an organism, and is preferably an organism.
- eukaryotes are not particularly limited, and include, for example, mammals including humans (humans, monkeys, mice, rats, hamsters, pests, etc.), fishes (zebrafish, etc.), and insects (silkworms, moths, Drosophila). And microorganisms such as plants and yeasts.
- the cell may be a cultured cell line containing a cancer cell, or a cell isolated from an individual or a thread. Further, the cells may be adherent cells or non-adherent cells.
- self-assembled cationic amphipathic aggregates for example, the aggregates prepared by the preparation method of the present invention
- cells eg, neurons, leukocytes, etc.
- non-adherent cells e.g., the aggregates prepared by the preparation method of the present invention
- “neural cells” and “white blood cells” include a cultured cell line derived from oriori and a cultured cell line derived from leukocyte, respectively.
- the cells are suspended in an appropriate medium several days before the larva with the hybrid and cultured under appropriate conditions, so that the cells are in a logarithmic growth phase at the time of inversion with the hybrid. Is preferred.
- the culture solution at the time of the inversion may be a serum-containing medium or a serum-free medium, but the serum concentration in the medium is preferably 20% or less, preferably 10% or less! / ,. This is because if the medium contains an excess of proteins such as serum, the removal of the complex from the cells may be inhibited.
- the cell concentration at the time of the insect is not particularly limited, and can be appropriately set in consideration of the type of the cell, etc., but is usually from 0.5 ⁇ 10 5 to 5 ⁇ 10 5 ce 11 s / mL, preferably rather it is 0. 5X 10 5 ⁇ 4 X 10 5 ce 1 1 s / mL, more preferably 0. 5 X 10 5 ⁇ 3 X 10 5 ce 1 1 s / mL, more preferably 1 X 10 5 ⁇ 3 X 10 5 ce 1 1 s / mL, and most preferably in the range of l X 10 5 ⁇ 2X 10 5 ce 1 1 s / mL.
- the above-mentioned complex-containing ⁇ is added to the medium containing the cells thus prepared.
- the amount of addition of the complex is not particularly limited and can be appropriately set in consideration of the number of cells, etc., but is usually 1 to 1000, preferably 1 to 500 L, more preferably 1 mL of the medium. It is in the range of l-300 / zL, more preferably l-200 / iL, most preferably 1-100 // L.
- the cells After adding the complex-containing medium to the medium, the cells are cultured.
- the temperature, humidity, CO 2 concentration, etc., during the culture are appropriately set in consideration of the type of cells.
- ⁇ In mammalian cells is usually about 3
- the culture time can also be appropriately set in consideration of conditions such as the type of cells to be used, but is usually 1 to 36 hours, preferably 1 to 24 hours, more preferably 1 to 12 hours, and still more preferably. It ranges from 2 to 8 hours, most preferably 3 to 6 hours. If the culture time is too short, the conjugate (nucleic acid or the like) will not be introduced into the cells, and if the culture time is too long, the cells may weaken.
- the compound is introduced into the cells by the above culture.
- the medium is replaced with a fresh medium, or the whole medium is added to the medium and the culture is further continued.
- the ⁇ medium preferably contains serum or trophic factors.
- the further culturing time can be appropriately set in consideration of the functions expected of the introduced compound (nucleic acid or the like).
- ⁇ Is usually 16 to 72 hours, preferably 16 to 60 hours, more preferably 16 to 48 hours, even more preferably 16 to 36 hours, and most preferably 16 to 24 hours.
- siRNA it is usually 16 to 72 hours, preferably 16 to 60 hours, more preferably 16 to 48 hours, and still more preferably 16 to 48 hours.
- ⁇ 36 hours most preferably 16-24 hours.
- the complex can be administered without particular limitation, for example, mammals including humans (humans, monkeys, mice, rats, hamsters, hamsters, etc.), fishes (zebrafish, etc.), birds (chicken, ostriches, etc.). Vertebrates, insects (silkworms, moths, etc.), plants, and the like.
- the method of administering the t-merge is not particularly limited as long as the ⁇ m-merger reaches the target cell, and the compound contained in the complex can be introduced into the cell.
- administration methods known per se oral administration, parenteral administration (intravenous administration, intramuscular administration, topical administration, dermal administration, subcutaneous administration, ⁇ , Etc.) can be appropriately selected.
- the dose of the complex is not particularly limited as long as the compound can be introduced into cells, and the type of administration, the method of administration, the type of compound to be introduced, the type and site of the target cell, etc.
- the single dose is about 0.001 mg to 100 000 as a complex. mg.
- Parenteral administration: ⁇ eg, intravenous administration, etc.
- ⁇ is generally, for example, in humans (as 60 kg), a single dose of about 0.0000 mg 0 0 mg.
- the dose can be administered in terms of 6 O kg.
- the use of the self-threaded cationic amphipathic molecular assembly makes it possible to introduce the conjugate into the cell with extremely high efficiency.
- an agent for introducing a compound into a cell in vitro or in vivo including an aggregating molecule assembly.
- the agent is delivered as a research reagent, drug, or the like.
- a desired compound can be easily introduced into cells.
- the cationic amphipathic molecular assembly that has been made into a self-filament fiber can be formulated in a conventional manner, as long as it is used as an agent for introducing the conjugate into cells.
- the self-fiberized cationic cationic amphiphilic molecular assembly may be used as such or as, for example, water or other physiologically acceptable liquid (eg, as described above). Water-soluble solvent, etc.) or as a suspension.
- the agent may itself contain excipients, vehicles, preservatives, stabilizers, binders and the like, which are physiologically acceptable in the mouth itself.
- the self-immobilized cationic amphiphilic molecular assembly may be used as it is or as a known pharmaceutically acceptable carrier, flavor, excipient, or base.
- Oral eg, tablet, capsule, etc.
- parenteral eg, drug
- Additives that can be incorporated into tablets, capsules, etc. include, for example, binders such as gelatin, corn starch, tragacanth, gum arabic, excipients such as crystalline cellulose, corn starch, gelatin, alginic acid, etc.
- Leavening agents such as Lubricants such as magnesium stearate, sweeteners such as sucrose, lactose or saccharin, and fragrances such as peppermint, cocoa oil or cherry are used.
- the unit dosage form is a capsule
- the above type of material can further contain a liquid carrier such as an oil or fat.
- a liquid carrier such as an oil or fat.
- the aqueous liquid for the preparation include an isotonic solution containing physiological saline, grape, and other auxiliary agents (eg, D-sorbitol, D-manthout / re, sodium chloride, etc.).
- agent if example embodiment, the alcohol (e.g.
- ethanol e.g propylene glycol, polyethylene da recall
- nonionic surfactants e.g., polysorbate 8 ⁇ ⁇ M, HC O- 5 0
- oily liquid for example, sesame oil, soybean oil and the like are used, and may be used in combination with solubilizers such as benzyl benzoate and benzyl alcohol.
- Examples of the above agents include a buffer (eg, phosphate buffer, sodium acetate buffer), a soothing agent (eg, benzalcoium chloride, pro-force hydrochloride, etc.), a stabilizer (eg, human serum albumin). , Polyethylene glycol, etc.), preservatives (eg, benzyl alcohol, phenol, etc.), antioxidants and the like.
- a buffer eg, phosphate buffer, sodium acetate buffer
- a soothing agent eg, benzalcoium chloride, pro-force hydrochloride, etc.
- a stabilizer eg, human serum albumin
- preservatives eg, benzyl alcohol, phenol, etc.
- antioxidants e.g, antioxidants and the like.
- the content of the self-threaded cationic amphipathic molecular assembly contained in these agents is particularly limited within the range in which the compound can be introduced into cells when used in the above method. There is no limitation, and it can be
- kits containing the compound and introducing the compound into cells can be prepared.
- the kit can further include all reagents and the like that can be used in the above method (for example, the above-mentioned water-soluble solvent, instructions describing the preparation protocol, a reaction vessel, and the like).
- a desired compound can be easily introduced into cells according to the method described above.
- the self contained in the agent of the present invention may be a complex with a compound desired to be introduced into cells.
- the present invention provides a kit for preparing a cationic amphiphilic, child assembly by the preparation method of the present invention.
- the kit contains at least the cationic amphiphilic molecule described above.
- the kit can further include any of the reagents used in the preparation of the present invention (eg, the above-mentioned water-soluble solvent, instructions describing the preparation protocol, reaction ⁇ !, etc.).
- a cationic amphiphilic molecular assembly for use in introducing a compound into cells can be easily prepared according to the above-mentioned preparation method.
- the present invention eliminates a kit for introducing a compound (such as a nucleic acid) into a cell by the method of the present invention.
- the kit contains at least the above-mentioned cationic amphiphilic monomer or an assembly thereof (an assembly made into a self-filament fiber).
- the kit further includes any reagents and the like that can be used in the above method (for example, a compound that is desired to be introduced into cells, a solvent that is soluble in ⁇ ⁇ , a written instruction describing a test protocol, a reaction vessel, and the like). Can be further included.
- the desired compound can be easily introduced into cells according to the method described above.
- the compound of formula (VI) (referred to as compound (VI)) was used as the cationic amphiphilic molecule.
- plasmid pQBI (Nippon Gene) was used as the plasmid DNA.
- Plasmid pQBI is a plasmid with the GFP gene inserted downstream of the CMV-IE promoter, and expresses GFP when introduced into cells.
- a complex of PQBI and an aggregate of compound (VI) was prepared.
- the results obtained when using the aggregate of the compound (VI) prepared at 25 ° C. are shown.
- As a conventional method 4.3 g of the ribosome of compound (VI) prepared at a temperature exceeding 4 and plasmid pQBI are added to 30 ⁇ L of serum-free medium and incubated for 5 minutes, and plasmid pQBI and compound (VI A complex with liposome was prepared. (Here, the results obtained using liposomes of compound (VI) prepared at 50 ° C are shown.)
- Hela human ovarian cancer cells
- Jurkat human leukemia cells
- SME mouse neural stem cells
- CH0 hamster ovary cells
- the cells were prepared in 0.3 mL of serum-free medium.
- the above-mentioned complex was admitted here, and cultured at 37 ° C. and 5% CO 2 for 4 hours. Further, 1 mL of a 10% FBS-containing medium was added, and the cells were cultured until the next day.
- the cells were observed under a fluorescence microscope.
- the compound of formula (VI) (referred to as compound (VI)) was used as the amphiphilic molecule.
- the target gene of the s iRNA used was EGFP, and the s i RNA used was Nippon Gene.
- 4.3 g of ribosomes of compound (VI) prepared at 40 ° C or higher and siRNA prepared at 20, 50, and 100 nM (concentration in the preparation) were used in a serum-free medium (30 L). Then, the mixture was incubated for 5 minutes to prepare a complex of siRNA and a liposome of compound (VI).
- the results obtained using the ribosome of compound (VI) prepared at 50 ° C are shown.
- CH0 cells stably expressing EGFP were used as cells.
- Cells were prepared in 0.3 mL of serum-free medium. The above complex was added thereto, and the cells were cultured at 37 ° C. and 5% CO 2 for 4 hours. Further, 1 mL of a 10% FBS-containing medium was added and cultured until the next day.
- the expression level of the EGFP gene was calculated as a relative value when the fluorescence intensity of the negative control cells was 100%.
- the compound of formula (VI) (referred to as compound (VI)) was used as the amphiphilic molecule.
- the following reagents were mixed by gentle pipetting.
- a fluorescent-labeled siRNA labeled with Cy-3 was used as a nucleic acid molecule in order to observe the molecular eaves of the molecule. After working the mixture at room temperature for 5 minutes, the prepared ⁇ ⁇ was used.
- BALB / c mice (7 weeks old) were exposed through the tail vein.4 hours after the injection, the lungs, liver, spleen and kidney were removed from the mice, cut into small pieces, and observed with a fluorescence microscope. Table 3 and Table 1 show the results.
- Table 1 shows the results of siRNA introduction into each organ of the mouse.
- ++ indicates that the siRNA was introduced into about 25% of the cells
- + indicates that the siRNA was introduced into about 10% of the cells
- soil was slightly introduced, and Respectively.
- the siRNA could be introduced into each ⁇ in the living body by using the compound (VI).
- the efficiency of introduction into the spleen and liver was excellent.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005516037A JPWO2005054486A1 (ja) | 2003-12-05 | 2004-12-03 | 遺伝子導入試薬調製法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-408231 | 2003-12-05 | ||
JP2003408231 | 2003-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005054486A1 true WO2005054486A1 (ja) | 2005-06-16 |
Family
ID=34650393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/018426 WO2005054486A1 (ja) | 2003-12-05 | 2004-12-03 | 遺伝子導入試薬調製法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005054486A1 (ja) |
WO (1) | WO2005054486A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009528258A (ja) * | 2006-03-01 | 2009-08-06 | 福岡県 | ペプチド脂質を含んだキャリア及びそれを用いた化合物の細胞内導入法 |
WO2012132022A1 (en) | 2011-03-30 | 2012-10-04 | Fukuoka Prefectural Government | Agent for promoting gene transfer and method of gene transfer using the same |
US9011196B2 (en) | 2013-03-15 | 2015-04-21 | Global Marketing Enterprise (Gme) Ltd. | Developmental activity gym for babies |
US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
EP3686184A3 (en) * | 2015-06-24 | 2020-08-26 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02135092A (ja) * | 1988-11-14 | 1990-05-23 | Bitamin Kenkyusho:Kk | 細胞への遺伝子導入法 |
JPH10139685A (ja) * | 1996-11-11 | 1998-05-26 | Fukuoka Pref Gov | 合成二分子膜から成るアジュバントとその使用法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0564739A (ja) * | 1991-09-05 | 1993-03-19 | Canon Inc | 巨大リポソームの調製方法 |
JPH069710A (ja) * | 1992-06-25 | 1994-01-18 | Canon Inc | 巨大リポソームの調製方法、lb膜製造装置及び該装置を用いたlb膜の製造方法 |
-
2004
- 2004-12-03 JP JP2005516037A patent/JPWO2005054486A1/ja active Pending
- 2004-12-03 WO PCT/JP2004/018426 patent/WO2005054486A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02135092A (ja) * | 1988-11-14 | 1990-05-23 | Bitamin Kenkyusho:Kk | 細胞への遺伝子導入法 |
JPH10139685A (ja) * | 1996-11-11 | 1998-05-26 | Fukuoka Pref Gov | 合成二分子膜から成るアジュバントとその使用法 |
Non-Patent Citations (1)
Title |
---|
KOKUBU T. ET AL: "Gosei Nibunshi Maku-Yuki Bunshi no Jiko Soshikika", BIOPHYSICS, vol. 21, no. 6, 1981, pages 289 - 301, XP002990298 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009528258A (ja) * | 2006-03-01 | 2009-08-06 | 福岡県 | ペプチド脂質を含んだキャリア及びそれを用いた化合物の細胞内導入法 |
JP4911416B2 (ja) * | 2006-03-01 | 2012-04-04 | 福岡県 | ペプチド脂質を含んだキャリア及びそれを用いた化合物の細胞内導入法 |
WO2012132022A1 (en) | 2011-03-30 | 2012-10-04 | Fukuoka Prefectural Government | Agent for promoting gene transfer and method of gene transfer using the same |
US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
US10000447B2 (en) | 2011-06-08 | 2018-06-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
US10100004B2 (en) | 2011-06-08 | 2018-10-16 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
US10669229B2 (en) | 2011-06-08 | 2020-06-02 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
US9011196B2 (en) | 2013-03-15 | 2015-04-21 | Global Marketing Enterprise (Gme) Ltd. | Developmental activity gym for babies |
EP3686184A3 (en) * | 2015-06-24 | 2020-08-26 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
US11384051B2 (en) | 2015-06-24 | 2022-07-12 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005054486A1 (ja) | 2007-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Behr | Synthetic gene transfer vectors II: back to the future. | |
CN103906504B (zh) | 制备用于药物递送的脂质纳米颗粒的方法 | |
CA3145913A1 (en) | Nanomaterials containing constrained lipids and uses thereof | |
DE69822473T2 (de) | Lipid-polyamid-konjugate und zusammensetzungen zur verabreichung von nucleinsäuremolekülen | |
EP3796893A1 (en) | Delivery of dna | |
JP6280120B2 (ja) | 干渉rnaの内在性メカニズムを調節することができる核酸配列を送達するための製剤 | |
KR20140041593A (ko) | 아미노 지질, 이의 합성 및 이의 용도 | |
JP2007112768A (ja) | 肝指向性リポソーム組成物 | |
JP6887020B2 (ja) | 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット | |
EP0905254A2 (de) | Mit biologisch verträglichen niedermolekularen Polyethyleniminen assoziierte DNA-Vektor | |
US20030162293A1 (en) | Cell transfection compositions comprising genetic material, an amphipathic compound and an enzyme inhibitor and method of use | |
JP2010059064A (ja) | 薬物送達複合体 | |
DE69928679T2 (de) | Kationische dendrimer-verbindungen und deren verwendung als oligonucleotid/polynucleotid-träger | |
DE4110409C2 (de) | Neue Protein-Polykation-Konjugate | |
US11252957B2 (en) | Nucleic acid-peptide capsule complexes | |
WO2005054486A1 (ja) | 遺伝子導入試薬調製法 | |
JP2023171937A (ja) | 改変型piggyBacトランスポゼースのポリペプチド、それをコードするポリヌクレオチド、導入キャリア、キット、細胞のゲノムに目的配列を組込む方法及び細胞製造方法 | |
JP6826014B2 (ja) | 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット | |
WO2022266083A2 (en) | Engineered polynucleotides for cell-type or microenvironment-specific expression | |
US10961547B2 (en) | Multifunctional metallic nanoparticle-peptide bilayer complexes | |
EP1007549B1 (en) | Compositions and methods for highly efficient transfection | |
WO2012017119A2 (es) | Vectores no virales para terapia génica | |
JP2000510334A (ja) | 原核生物rnaポリメラーゼ自己遺伝子を利用する細胞質遺伝子発現系 | |
WO2024131403A1 (zh) | 基于核酸适体的脾脏及其亚细胞的mRNA靶向递送系统 | |
US20230092306A1 (en) | Substance delivery carrier and composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005516037 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |